The Cystic Fibrosis Foundation has announced a grant of up to $3.3 million to Polyphor AG in support of efforts to develop an antibiotic that targets multi-drug resistant infections in individuals with cystic fibrosis.
The funding will support a Phase 1b/2a clinical trial, expected to start in late 2021, of inhaled murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa. According to the foundation, about 17 percent of individuals with CF who had Pseudomonas infections in 2019 had a multi-drug resistant strain; an inhaled version of the antibiotic has the potential to make it easier for someone to take the drug from home. The drug, which targets the outer membrane of bacteria, also might have certain advantages over broad-spectrum antibiotics.
"A significant number of people with CF have multi-drug resistant strains of Pseudomonas each year that require IV antibiotics and hospitalization," said CFF vice president of clinical research JP Clancy. "We hope to determine if the inhaled version of this new medicine could provide an alternative treatment option for people with CF that could potentially reduce their treatment burden."